Will New Jersey’s annual-average employment in Pharmaceutical and Medicine Manufacturing for 2026 be above 30,300 jobs?

- [2026-10-17] The BLS series SMU34000003232540001 (NSA, thousands) shows 2026 monthly values of Jan 29.5, Feb 29.6, Mar 29.3, Apr 29.2, May 29.4, Jun 29.5, Jul 29.6 and Aug 29.5 (preliminary). Aug is the latest month. Sep–Dec are not yet published. https://data.bls.gov/timeseries/SMU34000003232540001 - [2026-10-17] The BLS API returns the same values, with Aug 2026 flagged "latest" and preliminary. https://api.bls.gov/publicAPI/v2/timeseries/data/SMU34000003232540001?startyear=2024&endyear=2026 - [2026-10-17] My arithmetic on the BLS data: the Jan–Aug 2026 mean is 29.45 (sum 235.6). A 2026 annual average above 30.3 would need a sum above 363.6, so Sep–Dec would have to average about 32.0. Every month since Jan 2024 has been 31.2 or lower, so that is far outside the recent range. https://data.bls.gov/timeseries/SMU34000003232540001 - [2026-10-17] The 2025 monthly values are 30.7 in Jan, easing to 30.3 in Aug, 30.0 in Sep, 29.9 in Oct, 29.7 in Nov and 29.9 in Dec. By my arithmetic the 2025 annual mean is about 30.4. The 30.3 threshold sits just below that. The 2026 level has run roughly 0.9–1.0 below 2025's level. https://data.bls.gov/timeseries/SMU34000003232540001 - [2026-10-17] The series peaked at 31.2 in Jul–Aug 2024 and has trended down since. Its low in the past year was 29.2 in Apr 2026. https://data.bls.gov/timeseries/SMU34000003232540001 - [2026-09-18] The BLS state release for August 2026 was published on this date. It said payroll employment was essentially unchanged in 46 states, and it gave no sign of a sharp NJ pharma surge. https://www.bls.gov/news.release/laus.nr0.htm - [2026-09-18] BLS says the September 2026 state employment release is scheduled for 2026-10-20, 10:00 ET. It will add the Sep 2026 value and revise Aug. https://www.bls.gov/sae/ - [2026-07-22] FRED's seasonally adjusted version of the series read 29.25 in Jun 2026, 29.42 in May, 29.27 in Apr, 29.32 in Mar and 29.73 in Feb. This agrees with the flat-to-down NSA picture. https://fred.stlouisfed.org/series/SMU34000003232540001SA - [2026-04-02] NJ DOL published the 2025 benchmark data with the January 2026 estimates. Its Jan 2026 table shows Pharma and Medicine Manufacturing at 29,500, against 30,700 a year earlier (−1,200). That matches the BLS series. https://www.nj.gov/labor/assets/PDFs/Press/2026/PR%20Tables%20Jan%2026.pdf - [2026-07-16] NJ DOL's June 2026 release showed NJ manufacturing down 4,600 year over year. https://www.nj.gov/labor/lwdhome/press/2026/20260716_jobs.shtml - [2026-10-17] Remaining scheduled releases are the Sep data on Oct 20 and then the Oct, Nov and Dec data in late 2026 and early 2027. I did not find their exact dates. The January 2027 data release (around March 2027) normally brings the annual benchmark revision, and it falls before the 2027-04-30 close. The revision could shift 2026 levels, but I found nothing indicating a shift of about 0.9 or more. BOTTOM LINE: Eight months of 2026 data average about 29.45, roughly 0.85 below the 30.3 threshold. Reaching an annual average above 30.3 would need Sep–Dec to average about 32.0, so only a large benchmark revision could change the outcome. NOT FOUND: the Sep 2026 value (due Oct 20); exact dates for the Oct–Dec data and the March 2027 benchmark release; any news of major NJ pharma hiring or layoffs in the last 14 days; BLS's own published 2025 annual average (I computed it from the monthly values).

- [2026-10-17] BLS series SMU34000003232540001 (NSA, thousands) shows 2026 monthly values of Jan 29.5, Feb 29.6, Mar 29.3, Apr 29.2, May 29.4, Jun 29.5, Jul 29.6 and Aug 29.5 (preliminary). Their mean is about 29.45. https://data.bls.gov/timeseries/SMU34000003232540001 - [2026-10-17] To exceed 30.3 for the year, Sep–Dec would need to average about 32.0. That is about 2.5 thousand above August and above the series' all-time high in the data shown (31.2 in Jul–Aug 2024). https://data.bls.gov/timeseries/SMU34000003232540001 - [2026-10-17] The 2025 monthly path fell from 30.7 in Jan to 29.9 in Dec. The 2025 average is roughly 30.4, so the 30.3 threshold sits near the 2025 value. The 2026 level is about 1 thousand below it. https://data.bls.gov/timeseries/SMU34000003232540001 - [2026-10-17] Historical annual averages (my calculation from the monthly data): 2016 about 25.4, 2019 about 25.2, 2021 about 26.3, 2022 about 28.3, 2023 about 29.9 and 2024 about 30.8. The series rose from 2021 to 2024 and has declined since mid-2024. https://data.bls.gov/timeseries/SMU34000003232540001 - [2026-10-17] Historically, month-to-month moves are usually 0.1–0.4 thousand. The largest within-year jump I can see is the 2020 COVID dip of about 1.2 thousand in one month. A 2.5 thousand jump in a few months has no precedent in this series. https://data.bls.gov/timeseries/SMU34000003232540001 - [2026-04-02] The 2025 benchmark was already incorporated with the January 2026 release. NJDOL's January 2026 tables show Pharmaceutical and Medicine Manufacturing at 29,500. That compares with 29,900 in the prior month and 30,700 a year earlier, a change of -1,200 year over year. https://www.nj.gov/labor/assets/PDFs/Press/2026/PR%20Tables%20Jan%2026.pdf - [2026-07-22] FRED's seasonally adjusted series was 29.25 in Jun 2026, 29.42 in May, 29.27 in Apr, 29.32 in Mar and 29.73 in Feb. That is consistent with a flat to down trend. https://fred.stlouisfed.org/series/SMU34000003232540001SA - [2026-07-16] NJ manufacturing overall lost 4,600 jobs year over year as of June 2026. Total NJ manufacturing was flat at about 248–249 thousand from Mar to Aug 2026. https://www.nj.gov/labor/lwdhome/press/2026/20260716_jobs.shtml and https://www.bls.gov/regions/mid-atlantic/new_jersey.htm - [2026-10-17] The next annual benchmark revision would come with early-2027 data, around March 2027, which falls before the 2027-04-30 close. Benchmarks typically move a state industry series by a few tenths of a thousand to about 1 thousand. The 2026 data have so far not been re-benchmarked, so a revision upward of about 1 thousand is possible but would be unusual. - [2026-09] The national outlook is for pharma manufacturing employment to grow about 5% over 2024–34. This is a slow structural trend that does not suggest a sudden NJ jump. https://www.bls.gov/careeroutlook/2026/article/manufacturing.htm BOTTOM LINE: Eight months of 2026 data average about 29.45 thousand, roughly 0.85 thousand below the 30.3 threshold. Clearing it would need an unprecedented late-year surge to about 32 thousand, or a large upward benchmark revision. The outside view strongly favors No. NOT FOUND: Any published forecast, analyst estimate or sibling-market price for this series. Annual-average 2026 value (not yet published). Sep 2026 data (not yet released).

YES means: BLS reports a 2026 annual-average of above 30.3 thousand for New Jersey pharmaceutical and medicine manufacturing (series SMU34000003232540001, NSA). In practice that means the current ~29.5 level is lifted by a late-year surge or a benchmark revision. I could not find a strong, evidence-backed YES case. The best available arguments are weak. Each is below, with the prerequisite it would need. - [2026-10-15] **Newer data point.** The NJ DOL September 2026 release (BLS data, preliminary) shows total NJ manufacturing at 249,900 NSA-equivalent SA terms, up 1,000 on the month. Manufacturing is down 1,600 year over year, a much smaller gap than the −4,600 reported for June. The tables I could retrieve omit the pharma line, so I could not confirm a September pharma value. Prerequisite for YES: pharma would have to be driving this improvement, and nothing shows that. https://www.nj.gov/labor/lwdhome/press/2026/20261015_jobs.shtml - [2026-10-15] **Release timing.** NJ DOL's schedule puts October data on 2026-11-19. NJ DOL had already published September data on 2026-10-15, ahead of the BLS date of 10-20 cited by colleagues. Prerequisite for YES: a pharma jump in Sep–Dec large enough to lift the Sep–Dec average to about 32.0, per the colleagues' arithmetic. The September print is the first test, and it was not retrievable. https://www.nj.gov/labor/labormarketinformation/tools-resources/publications-reports/employmentpressrelease.shtml - [2026-07-23] **Hiring pipeline.** BeOne will invest $300M at its Hopewell, NJ campus and create about 120 jobs. The facility is not expected to be fully operational until 2029, so it adds almost nothing to 2026 payrolls. 120 jobs is about 0.4 thousand against a gap of roughly 0.85 thousand. https://www.pharmamanufacturing.com/industry-news/news/55393172/beone-medicines-to-invest-300m-in-new-jersey-manufacturing-expansion - [2026-07-27] **Same project, company source.** The company's own release confirms the 120 jobs and credits federal tax policy and NJ's "Next New Jersey Manufacturing Program." Reshoring incentives are real, but these are multi-year builds. https://www.insidernj.com/press-release/beone-medicines-expands-u-s-manufacturing-with-total-investment-of-more-than-1-billion-to-advance-innovative-cancer-medicines/ - [2026-06-29] **Other expansions.** Garonit Pharmaceutical is planning operations in Flanders, NJ, and Hovione is completing its East Windsor expansion in 2026. Both are small-scale and have no quantified 2026 headcount. https://www.areadevelopment.com/newsItems/6-29-2026/garonit-pharmaceutical-flanders-new-jersey.shtml and https://www.hovione.com/locations/hovione-new-jersey - [2026-10-02] **National manufacturing rebound.** BLS says US manufacturing is up 72,000 since a December 2025 low, including +9,000 in September. NJ pharma has not followed this rebound: its monthly values stayed in a 29.2–29.6 band through August (per colleagues' report). https://www.bls.gov/news.release/empsit.nr0.htm - [2026-04-02] **Benchmark mechanism, the only route that is not a surge.** The 2025 benchmark cut NJ's year-over-year nonfarm gain from 9,000 to 5,100, a downward revision. The next benchmark arrives around March 2027, before the 2027-04-30 close. For YES it would have to revise 2026 pharma up by about 0.85 thousand or more. The one precedent I found points down, not up. https://nj.gov/labor/lwdhome/press/2026/20260402_Jobs.shtml - [2026-09-04] **Benchmark input, QCEW.** BLS reports NJ covered employment essentially unchanged at 4,247,800 in March 2026 (QCEW). That is the data that drives benchmarks, and it gives no sign of a large upward gap for NJ. I found no pharma-specific QCEW figure. https://www.bls.gov/regions/mid-atlantic/news-release/countyemploymentandwages_newjersey.htm BOTTOM LINE: The single most likely path to YES is an upward 2027 benchmark revision of about 0.9 thousand or more, combined with flat-to-rising Sep–Dec prints. Nothing I found supports it: the announced hiring is small and slow-starting, and the one prior benchmark moved down. This dimension has no strong evidence-backed case. NOT FOUND: the September 2026 NJ pharma value (the NJ DOL table's pharma line was truncated in both fetches); any pharma-specific QCEW or benchmark-preview figure; any NJ pharma layoff or hiring news that would move 2026 payrolls by ~1 thousand.

YES means: BLS reports a 2026 annual average for NJ Pharmaceutical and Medicine Manufacturing (SMU34000003232540001) above 30.3 thousand. - [2026-08-28] BLS's preliminary state benchmark covers March 2026. It gave an average absolute state revision of 0.4% of total nonfarm employment, so it is a headline total-nonfarm figure. The release includes no NJ pharma detail. A 0.4% typical revision is far too small to close a gap of about 2.9% (0.85 of 29.45). It would take an NJ-specific, industry-specific revision of roughly 7x the typical state revision. https://www.bls.gov/news.release/archives/presae_08282026.htm - [2026-08-28] The national preliminary benchmark for March 2026 was only -79,000 (-0.1%). That is a downward revision, and the direction does not support an upward lift to payroll levels. https://www.bls.gov/ces/ - [2026-08-28] The final benchmark was originally scheduled for "March 2027" with the January 2027 state release. It will revise NSA data from April 2025 to December 2026. The final revision still lands before the 2027-04-30 close, but it can only help YES if it adds about 0.9 thousand to every 2026 month. The post-benchmark months (Apr–Dec 2026) are also subject to revision, but that is a smoothing of the sample trend, not a level reset. https://www.bls.gov/news.release/archives/presae_08282026.htm - [2026-09-23] BMS filed a third 2026 NJ WARN notice, for 265 jobs. Separations run from Dec 17, 2026 to May 21, 2027. Its 2026 NJ cuts total 718. These are corporate HQ and commercial roles and may fall partly outside NAICS 3254. They still point to flat or declining headcount in Sep–Dec, not a surge. https://nj1015.com/bristol-myers-squibb-layoffs-nj/ - [2026-09-23] Novartis posted four East Hanover notices totaling 572 jobs: 114 in March, 60 in April, 76 in May and 322 in July. Merck posted 142 at Rahway (88 in June, 54 in September). Together with BMS that is more than 1,400 NJ positions in nine months. https://www.finalroundai.com/blog/bristol-myers-squibb-layoffs - [2026-10-08] BioSpace says J&J has a 87-person cut in New Brunswick effective Dec 18, after a 56-person cut completed Aug 21. Merck's 54-person cut runs Dec 11 to Jan 4. Novartis's 322-person cut took effect Oct 2, which falls in the unpublished Oct data. BioSpace also names NJ the hardest-hit state in Q3. Several dated separations land in Oct–Jan, which argues against a Sep–Dec rebound. https://www.biospace.com/job-trends/q3-layoffs-down-yoy-with-90-fewer-biopharma-employees-affected - [2026-10-08] Q3 2026 biopharma layoffs were the lowest quarterly total since BioSpace began tracking, at 2,568 people. This is the one counterpoint to a pure decline story. Even so, lower layoff volume is not net hiring, and nothing found shows large NJ pharma manufacturing hiring. https://www.biospace.com/job-trends/q3-layoffs-down-yoy-with-90-fewer-biopharma-employees-affected - [2026-10-17] Resolution technicality, as I read the rules (not confirmed on a fetched BLS page): the contract says "annual-average employment for 2026" on the NSA series. BLS publishes the annual average only after the December data, and the Dec 2026 state release is expected in January 2027. It should be available before the close. I did not retrieve BLS's date for this release. If the annual average is not shown on BLS pages, the resolver would use the mean of the 12 months. The fixed 30.3 threshold means the 2025 revision is irrelevant. https://www.bls.gov/sae/ - [2026-10-17] Deadline arithmetic: the 2026 mean is 29.45 from eight months. Each month in Sep–Dec adds about 1/12 of its value to the annual mean. Even a Dec print of 31.2, the series high, with Sep–Nov at 29.5 gives a mean of about 29.7. The best-case path without a benchmark revision still falls about 0.6 short. This follows from the colleagues' reported data and my own calculation. BOTTOM LINE: This is a strong No case. The reported Jan–Aug data average 0.85 below the line, and the post-August WARN calendar and the small national benchmark (-0.1%) offer no route to a 32.0 Sep–Dec average. Only an NJ pharma-specific upward benchmark of about 0.9 thousand or more could produce Yes, and nothing found suggests one. NOT FOUND: The Sep 2026 print (due Oct 20). An NJ-specific preliminary benchmark figure for pharma. Any Philadelphia Fed early-benchmark figure for NJ (the PDF was found but not read for NJ). BLS's exact date for the Dec 2026 state release. Any NJ pharma manufacturing hiring announcement.